Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Funda Meric-BernstamMichael W LloydSoner KocYvonne A EvrardLisa Meier McShaneMichael T LewisKurt W EvansDali LiLawrence V RubinsteinAlana L WelmDennis A DeanAnuj SrivastavaJeffrey W GroverMin Jin HaHuiqin ChenXuelin HuangKaushik VaradarajanJing WangJack A RothBryan E WelmRamaswamy GovindanLi DingSalma KaocharNicholas MitsiadesLuis G Carvajal CarmonaMeenhard HerylynMichael A DaviesGeoffrey I ShapiroRyan C FieldsJose G TrevinoJoshua C Harrellnull nullJames H DoroshowJeffrey H ChuangJeffrey A MoscowPublished in: Molecular cancer therapeutics (2024)
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.